CHMP Recommends Denecimig for Hemophilia A

Company Novo Nordisk Event Type Regulatory Recommendation (CHMP Positive Opinion) Modality Bispecific Factor VIII-Mimetic Antibody Asset Denecimig (Frehemgo) Target Bridges Activated Factor IX and Factor X on Platelet Surfaces Disease Area Hemophilia A Summary EMA’s Committee for Medicinal Products for Human Use adopted a positive…